CI Global Health Sciences Corporate Class

Series P USD
 

Fund overview

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

Fund details

description of elementelement value
Inception date May 2017
CAD Total net assets ($CAD)
As at 2024-07-30
$167.8 million
NAVPS
As at 2024-08-15
$10.4015
MER (%)
As at 2024-03-31
0.24
Management fee (%) Negotiable
Asset class Sector Equity
Currency USD
Minimum investment $500 initial/$25 additional
Distribution frequency Quarterly
Last distribution $0.1669

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

FUND CODES

P 90324
A ISC 301
DSC SO* 401
LL SO 1401
F 324
*No new purchases directly into switch only funds.

Performance2 As at 2024-07-31

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
9.98% 0.60% 6.60% 8.65% 13.72% 2.00% 8.78% - 6.82%
*Since inception date

Distribution history3

Payable date Total
2022-03-25 0.1669
2021-03-26 0.0563
2020-12-18 0.0892
2020-09-25 0.0844
2020-06-26 0.0615
Payable date Total
2020-03-20 0.1428
2019-12-13 0.0890
2019-09-27 0.0991
2019-06-21 0.0930
2019-03-22 0.1458

Management team

First we'll display the Team Company and then the Team members
Greg Quickmire
Peter Hofstra

CI Global Health Sciences Corporate Class

Series P USD
 
Portfolio allocations4 As at 2024-07-31
Asset allocation (%)
  • US Equity 78.22
  • International Equity 21.10
  • Cash and Equivalents 0.69
  • Other -0.01
Sector allocation (%)
  • Healthcare 95.44
  • Exchange Traded Fund 2.79
  • Consumer Services 1.09
  • Cash and Cash Equivalent 0.69
  • Other -0.01
Geographic allocation(%)
  • United States 78.78
  • Denmark 7.45
  • United Kingdom 6.43
  • Switzerland 4.47
  • Germany 2.80
  • Canada 0.08
  • Other -0.01
Top holdings
Sector (%)
1. UnitedHealth Group Inc Healthcare Services 10.78%
2. Eli Lilly and Co Drugs 10.04%
3. Novo Nordisk A/S Cl B Drugs 7.45%
4. AstraZeneca PLC Drugs 6.41%
5. Merck & Co Inc Drugs 5.55%
6. Anthem Inc Healthcare Services 5.22%
7. Zoetis Inc Cl A Drugs 4.61%
8. Thermo Fisher Scientific Inc Healthcare Equipment 4.59%
9. AbbVie Inc Drugs 3.88%
10. Cigna Corp Healthcare Services 3.33%
11. Boston Scientific Corp Healthcare Equipment 3.07%
12. Intuitive Surgical Inc Healthcare Equipment 2.84%
13. Stryker Corp Healthcare Equipment 2.82%
14. Humana Inc Healthcare Services 2.82%
15. Roche Holding AG - Partcptn Drugs 2.80%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.